Inovio Pharmaceuticals, Inc. INO was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which …
The stock closed up 2.94% at $4.90. “The shared goal of Inovio and CEPI is for the Lassa and MERS vaccines to be available as soon as possible for emergency use,” Inovio and COPI said in this joint statement. The coalition has raised …
2017 was shaping up to be a good year for Inovio Pharmaceuticals (NASDAQ: INO). The stock was up more than 15% halfway through the year. And then shareholders got the bad news. In July, Inovio announced yet another dilutive stock …
Inovio Pharmaceuticals (NASDAQ: INO) continues to take investors on a roller coaster ride. The biotech stock was up close to 25% by late May, only to give up all of those gains and then some. A dilutive stock offering in July zapped all …
Inovio's shares, by contrast, appear to have simply followed the broader biotech industry lower last month, evinced by the poor performance of the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) in October. Inovio took a particularly hard …